Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vetrix is a regenerative medicine company dedicated to the veterinary market, specializing in extracellular matrix (ECM) technology. The company's flagship technology, BioSIS, is a naturally occurring scaffold derived from porcine small intestinal submucosa that facilitates tissue repair and regeneration in animals. Vetrix provides a range of products for applications such as wound management, surgical soft tissue repair, and ophthalmic treatments. Their products are designed to promote constructive remodeling of host tissue, offering an alternative to synthetic materials and reducing scar tissue formation. Headquartered in West Lafayette, Indiana, Vetrix leverages decades of research in ECM biology to improve clinical outcomes for companion and large animals.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vetrix BioSIS.